Report on consensus conference on cervical cancer screening and management

Miller, Anthony B.; Nazeer, Saloney; Fonn, Sharon; Brandup-Lukanow, Assia; Rehman, Rakshanda; Cronjé, H.S.; Sankaranarayanan, Rengaswamy; Koroltchouk, Valentin; Syrjänen, Karí; Singer, Albert; Onsrud, Mathias

doi:10.1002/(sici)1097-0215(20000501)86:3<440::aid-ijc22>3.0.co;2-a

Cited by 147 publications

(117 citation statements)

References 15 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 Programmatic strategies should assure that all women aged 65+ who have never had a Pap test are screened at least once. However, in provinces with limited resources, priority should be given to screening women aged 35-64.…”

Section: Findings and Discussionmentioning

confidence: 99%

Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina

Arrossi¹,

Ramos

Paolino

et al. 2008

Reproductive Health Matters

Self Cite

View full text Add to dashboard Cite

Section: Findings and Discussionmentioning

confidence: 99%

Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina

Arrossi¹,

Ramos

Paolino

et al. 2008

Reproductive Health Matters

Self Cite

View full text Add to dashboard Cite

“…In addition, fewer ASCUS and CIN1 results (4 and 122) were reported than CIN2 or worse results (153), suggesting that either the quality of cytology-processing is poor or cytology is used primarily for diagnosis. To ensure adequate skills, it is recommended that between 20,000 and 30,000 cytology smears be processed annually in a laboratory [1]. During 1999, seven laboratories processed around 30,000 smears, suggesting that the quality of analysis in regional laboratories is inadequate.…”

Section: Discussionmentioning

confidence: 99%

“…Screening programs to detect precancerous lesions on the cervix using conventional cytology (Papanicolaou) have been successful in reducing overall mortality in developed countries [1]. Yet, many middle-income developing countries have found that even after offering cytology-based screening, it has been difficult to reduce mortality due to cervical cancer [2].…”

Section: Introductionmentioning

confidence: 99%

Follow-up care of women with an abnormal cytology in a low-resource setting

Gage

Ferreccio

Gonzales

et al. 2003

Cancer Detection and Prevention

View full text Add to dashboard Cite

Study purpose: We ascertained the follow-up care after an abnormal cytology (Papanicolaou) screening in the San Martín region of Perú and assessed the status of women who had not received adequate care. Basic procedures: We identified women with an abnormal cytology and assessed their medical records, laboratory registries, death certificates and interviewed them at home. Re-screening, diagnosis and treatment were offered. Main findings: Only 46 (25%) of the 183 women identified received appropriate follow-up care. At re-screening 31 (34%) had a normal result, 9 (10%) were diagnosed with CIN1 and 50 (56%) had CIN2 or worse. Principal conclusions: In this setting, follow-up care after an abnormal cytology was very poor and could explain the lack of impact of cervical cancer screening. Women with an abnormal cytology constitute a high-risk group that should be a priority for health services.

show abstract

“…1 Of these 4,481 women, 52 were excluded for missing either HC2 or AHPV test; 2 Total number of women having both tests and cytology. These women constitute the analysis data set unless noted otherwise; 3 Original cytology, with abnormal diagnosis based on ASC-US cut-off; 4 Manufacturer recommended cut-off; 5 Colposcopy was obtained on a simple random sample of women with normal cytology who were HC2 negative and AHPV negative. Also the few vaginal lesions with no CIN were excluded from the analysis.…”

Section: Hpv Testingmentioning

confidence: 99%

Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study

Monsonégo

Hudgens

Zerat³

et al. 2010

Intl Journal of Cancer

129

View full text Add to dashboard Cite

The APTIMA V R HPV Assay (AHPV) allows detection of 14 high-risk human papillomavirus (HPV) RNA types in cervical specimens. Until present, the assay has been compared to HPV DNA tests only in triage settings. Herein, we compare AHPV with a DNA assay (Hybrid Capture V R 2; HC2) and liquid-based cytology (LBC; using PreservCyt V R ThinPrep liquid Pap) in a screening setting (French APTIMA screening evaluation [FASE] study). Women (N 5 5,006) aged 20-65 were screened by gynecologists in 17 private practices in Paris, France. One cervical specimen was collected and tested with LBC, AHPV and HC2 assays. Women were referred to colposcopy if they were ASC-US1 in LBC or HPV positive in either HPV assay. To control for verification bias, a random group (14%) with normal LBC and dually HPV negative tests underwent colposcopy. Data from 4,429 women were analyzed. Sensitivity, specificity and predictive values were calculated for the three tests. AHPV and HC2 were highly sensitive for CIN21 (92.0% and 96.7%) and CIN31 (95.7% and 95.3%) detection and much more sensitive than LBC (69.1% for CIN21 and 73.3% for CIN31). Specificity of AHPV was higher than that of HC2, but similar to that of LBC (p < 0.001). Combining LBC with either HPV test slightly increased sensitivity but compromised specificity. AHPV assay is both specific and sensitive for the detection of high-grade precancerous lesions and may be considered as an option for routine cervical cancer screening for women over 20 years of age.Invasive cervical cancer (ICC) is the second most frequent female cancer worldwide, 1 with an estimation of 493,000 cases annually. ICC incidence and mortality rates have dramatically declined over the past five decades in developed countries, largely due to screening programs based on conventional cervical Papanicolaou (Pap) smears. 2,3 Conventional Pap smear screening, however, has limited sensitivity, positive predictive value (PPV) and reproducibility, which limits its use for primary screening. 3,4-7 Liquid-based cytology (LBC) has been shown to be more sensitive than conventional

show abstract

Report on consensus conference on cervical cancer screening and management

Cited by 147 publications

References 15 publications

Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina

Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina

Follow-up care of women with an abnormal cytology in a low-resource setting

Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study

Contact Info

Product

Resources

About